Results 31 to 40 of about 2,198,265 (159)

Progression of echocardiographic parameters and prognosis in ATTR cardiac amyloidosis [PDF]

, 2022
AIMS: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly diagnosed disease. Echocardiography is widely utilized, but studies to confirm the value of echocardiography for tracking changes over time are not available. We sought to describe: (
Quarta, Candida C, Porcari, Aldostefano, Buonamici, Lodovico, Riefolo, Mattia, Bandera, Francesco, Razvi, Yousuf, Hawkins, Philip N, Potena, Luciano, Gillmore, Julian D, Patel, Rishi, Rowczenio, Dorota, Moon, James, Dal Passo, Beatrice, Whelan, Carol, Chacko, Liza, Moody, William E, Venneri, Lucia, Brown, James, Lachmann, Helen, Petrie, Aviva, Manisty, Charlotte, Wechelakar, Ashutosh, Martinez-Naharro, Ana, Steeds, Richard P, Rapezzi, Claudio, Lazari, Jonathan, Knight, Daniel, Leone, Ornella, Ioannou, Adam, Karia, Nina, Fontana, Marianna, Gilbertson, Janet A   +31 more
core   +1 more source

Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden

Annals of Medicine, 2023
Aims To estimate healthcare resource use and direct healthcare costs of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Sweden over 12 months across severity stages as defined by the New York Heart Association (NYHA).
Frida Hjalte, Jenny M. Norlin, Linda Alverbäck-Labberton, Katarina Johansson, Gerhard Wikström, Per Eldhagen   +5 more
doaj   +1 more source

How did transthyretin amyloid cardiomyopathy progress in patients who took placebo in the study ATTR-ACT? A plain language summary

, 2022
What is this plain language summary about? This plain language summary describes some results of a study called ATTR-ACT. This was the first large study to include people with wild-type and hereditary transthyretin amyloid cardiomyopathy (ATTR-CM for ...
Sultan, Marla B, Judge, Daniel P, Gundapaneni, Balarama, Hoffman, James E, Keohane, Denis, Nativi-Nicolau, Jose, Grogan, Martha, Daniel P Judge, Martha Grogan, Balarama Gundapaneni, James E Hoffman, Marla B Sultan, Jose Nativi-Nicolau, Denis Keohane   +13 more
core   +1 more source

Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy [PDF]

Transthyretin amyloid cardiomyopathy (ATTR-CM) has been traditionally considered a rare and inexorably fatal condition. ATTR-CM now is an increasingly recognized cause of heart failure (HF) and mortality worldwide with effective pharmacological ...
Porcari, Aldostefano, Sinagra, Gianfranco, Fontana, Marianna, Hawkins, Philip N, Gillmore, Julian D   +4 more
core   +4 more sources

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Increased dipeptidyl peptidase 4 in patients with concomitant transthyretin cardiac amyloidosis and severe aortic stenosis

International Journal of Cardiology: Heart & Vasculature
Background: Due to overlapping symptoms and signs, it can be challenging to diagnose transthyretin amyloid cardiomyopathy (ATTR-CM) in the setting of concomitant aortic stenosis.
Margrethe Flesvig Holt, Annika E. Michelsen, August Flø, Kristoffer Russell, Jan Otto Beitnes, Sophie Foss Kløve, Anders Hodt, Lars Gullestad, Pål Aukrust, Einar Gude, Kaspar Broch, Thor Ueland   +11 more
doaj   +1 more source

Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis

JACC. CardioOncology, 2020
Background: With increasing diagnoses and available treatment options for transthyretin amyloidosis cardiomyopathy (ATTR-CM), risk stratification of ATTR-CM patients is imperative.
Richard K. Cheng, MD, MSc, Wayne C. Levy, MD, Alexi Vasbinder, RN, Sergio Teruya, MD, Jeffeny De Los Santos, MD, Douglas Leedy, MD, Mathew S. Maurer, MD   +6 more
doaj   +1 more source

Diagnostic algorithm in transthyretin amyloidosis with cardiomyopathy [PDF]

Българска кардиология, 2020
Transthyretin cardiac amyloidosis is a restrictive cardiomyopathy ((ATTR-CM), caused by an extracellular deposition of insoluble amyloid fibrils in the myocardium.
Mariana Gospodinova, Elena Kinova, Iana Simova, Yoto Yotov, Marina Garcheva, Galina Kirova, Kamelia Genova, Albena Todorova, Stayko Sarafov, Ivailo Tournev, Mariya Tokmakova, Vasil Velchev   +11 more
doaj   +3 more sources

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Transthyretin amyloid cardiomyopathy in aortic stenosis patients scheduled for transcatheter aortic valve implantation

ESC Heart Failure
Aims The prevalences of aortic stenosis (AS) and transthyretin amyloid cardiomyopathy (ATTR‐CM) increase with age. Identification of occult ATTR‐CM in patients with AS can help explain out‐of‐proportion myocardial dysfunction, aid in prognostication and ...
Margrethe Flesvig Holt, August Flø, Esra Kaya, Sophie Foss Kløve, Hege Martinsen, Kristine Amlie, Petter Storsten, Thomas Misje Mathiisen, Kristoffer Russell, Christian Hesbø Eek, Helge Skulstad, Melinda Raki, Lars Gullestad, Anders Hodt, Einar Gude, Kaspar Broch   +15 more
doaj   +1 more source